Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

被引:218
作者
Zhu, Meng-Lei
Kyprianou, Natasha [1 ]
机构
[1] Univ Kentucky, Med Ctr, Coll Med, Dept Urol, Lexington, KY 40536 USA
关键词
D O I
10.1677/ERC-08-0084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Androgens promote the growth and differentiation of prostate cells through ligand activation of the androgen receptor (AR). Sensitization of the androgenic response by multifunctional growth factor signaling pathways is one of the mechanisms via which AR contributes to the emergence of androgen-independent prostate tumors. The ability of AR to cross-talk with key growth factor signaling events toward the regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells is established. In this paper, we review the functional interaction between AR and an array of growth factor signal transduction events (including epidermal growth factor; fibroblast growth factor; IGF1; vascular endothelial growth factor; transforming growth factor-beta) in prostate tumors. The significance of this derailed cross-talk between androgens and key signaling networks in prostate cancer progression and its value as a therapeutic forum targeting androgen-independent metastatic prostate cancer is discussed.
引用
收藏
页码:841 / 849
页数:9
相关论文
共 100 条
  • [1] An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells
    Aaronson, David S.
    Muller, Melissa
    Neves, Susana R.
    Chung, Wen-Chen
    Jayaram, Gomathi
    Iyengar, Ravi
    Ram, Prahlad T.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2007, 270 (1-2) : 50 - 56
  • [2] Stat3 promotes metastatic progression of prostate cancer
    Abdulghani, Junaid
    Gu, Lei
    Dagvadorj, Ayush
    Lutz, Jacqueline
    Leiby, Benjamin
    Bonuccelli, Gloria
    Lisanti, Michael P.
    Zellweger, Tobias
    Alanen, Kalle
    Mirtti, Tuomas
    Visakorpi, Tapio
    Bubendorf, Lukas
    Nevalainen, Marja T.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (06) : 1717 - 1728
  • [3] Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143
  • [4] TGF-β signaling in cancer -: a double-edged sword
    Akhurst, RJ
    Derynck, R
    [J]. TRENDS IN CELL BIOLOGY, 2001, 11 (11) : S44 - S51
  • [5] Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy
    Anastasiadis, AG
    Bemis, DL
    Stisser, BC
    Salomon, L
    Ghafar, MA
    Buttyan, R
    [J]. CURRENT DRUG TARGETS, 2003, 4 (03) : 191 - 196
  • [6] Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia
    Banham, Alison H.
    Boddy, Jane
    Launchbury, Rosalind
    Han, Cheng
    Turley, Helen
    Malone, Peter R.
    Harris, Adrian L.
    Fox, Stephen B.
    [J]. PROSTATE, 2007, 67 (10) : 1091 - 1098
  • [7] AKT1/PKBα is recruited to lipid rafts and activated downstream of PKC isotypes in CD3-induced T cell signaling
    Bauer, B
    Jenny, M
    Fresser, F
    Überall, F
    Baier, G
    [J]. FEBS LETTERS, 2003, 541 (1-3) : 155 - 162
  • [8] The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer
    Boddy, JL
    Fox, SB
    Han, C
    Campo, L
    Turley, H
    Kanga, S
    Malone, PR
    Harris, AL
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (21) : 7658 - 7663
  • [9] Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3K/AKT activation
    Bonaccorsi, L
    Marchiani, S
    Muratori, M
    Forti, G
    Baldi, E
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (10) : 604 - 614
  • [10] EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)
    Bonaccorsi, L
    Carloni, V
    Muratori, M
    Formigli, L
    Zecchi, S
    Forti, G
    Baldi, E
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (01) : 78 - 86